What is Global Atherosclerosis Drugs Market?
The Global Atherosclerosis Drugs Market is a vast and complex field that encompasses a wide range of medications designed to treat atherosclerosis, a condition characterized by the hardening and narrowing of the arteries due to plaque build-up. This market is a critical component of the global healthcare industry, as atherosclerosis is a leading cause of heart disease, stroke, and other serious health conditions. The market includes various types of drugs such as Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, among others. Corticosteroids are anti-inflammatory medications that can help reduce the inflammation in the arteries that contributes to atherosclerosis. PDE4 Inhibitors are a newer class of drugs that can help reduce inflammation and improve blood flow. Biologics are complex medications derived from living organisms that can help reduce inflammation and plaque build-up. Skin Barrier Emollients are used to treat skin conditions that can be associated with atherosclerosis, while CNI Immunosuppressants are used to suppress the immune system and reduce inflammation. These drugs are used in various settings including hospitals, clinics, retail pharmacies, and others. In hospitals and clinics, these drugs are often administered under the supervision of a healthcare professional. Retail pharmacies provide these medications for patients to use at home, often as part of a long-term treatment plan. Other settings may include home healthcare services, long-term care facilities, and others. The global Atherosclerosis Drugs market was valued at US$ 40180 million in 2022. It is expected to grow to US$ 43670 million by 2029, with a compound annual growth rate (CAGR) of 1.4% during the forecast period from 2023 to 2029. This growth is driven by a number of factors, including the increasing prevalence of atherosclerosis, advancements in drug development, and the growing global aging population.
Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others in the Global Atherosclerosis Drugs Market:
#GlobalAtherosclerosisDrugsMarket #Corticosteroids #PDE4Inhibitors #Biologics #SkinBarrierEmollients #CNIImmunosuppressants #Hospital #Clinic #RetailPharmacies #MarketGrowth
Hospital, Clinic, Retail Pharmacies, Other in the Global Atherosclerosis Drugs Market:
#グローバル動脈硬化症薬市場 #コルチコステロイド #PDE4阻害剤 #バイオロジクス #皮膚バリアエモリエント #CNI免疫抑制剤 #病院 #クリニック #小売薬局 #市場成長
Global Atherosclerosis Drugs Market Outlook:
#글로벌동맥경화증약시장 #코르티코스테로이드 #PDE4억제제 #바이오로직스 #피부배리어에몰리언트 #CNI면역억제제 #병원 #클리닉 #소매약국 #시장성장
| Report Metric | Details |
| Report Name | Atherosclerosis Drugs Market |
| Accounted market size in 2023 | US$ 40180 million |
| Forecasted market size in 2029 | US$ 43670 million |
| Base Year | 2023 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | GlaxoSmithKline, Sanofi, F. Hoffmann-L a Roche, Bayer, Novartis, Merck, Janssen Pharmaceutical, Amgen, Pfizer |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
